{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T13:03:56Z","timestamp":1758632636111},"reference-count":18,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2009,1,29]],"date-time":"2009-01-29T00:00:00Z","timestamp":1233187200000},"content-version":"vor","delay-in-days":2646,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["bpspubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["British J Pharmacology"],"published-print":{"date-parts":[[2001,11]]},"abstract":"<jats:p>\n<jats:list list-type=\"explicit-label\">\n<jats:list-item><jats:p>We aimed to characterize the 5\u2010HT receptors involved in the 5\u2010HT\u2010induced effect on electrically induced contractions of dog antrum longitudinal muscle <jats:italic>in vitro<\/jats:italic>.<\/jats:p><\/jats:list-item>\n<jats:list-item><jats:p>In the presence of <jats:sc>L<\/jats:sc>\u2010NOARG (0.1\u2003m<jats:sc>M<\/jats:sc>), electrical field stimulation (EFS) induced atropine\u2010 and tetrodotoxin\u2010sensitive contractions. Tetrodotoxin or atropine left any agonist tested ineffective. These EFS\u2010induced contractions were on average enhanced by 5\u2010HT (0.3\u2003\u03bc<jats:sc>M<\/jats:sc>), however, pronounced variation in the response to 5\u2010HT was observed. There were non\u2010significant trends of the selective 5\u2010HT<jats:sub>3<\/jats:sub> receptor antagonist granisetron (1\u2003\u03bc<jats:sc>M<\/jats:sc>), and methysergide (1\u2003\u03bc<jats:sc>M<\/jats:sc>; preventing interactions of 5\u2010HT with 5\u2010HT<jats:sub>1<\/jats:sub>, 5\u2010HT<jats:sub>2<\/jats:sub>, 5\u2010ht<jats:sub>5<\/jats:sub>, 5\u2010HT<jats:sub>6<\/jats:sub> and 5\u2010HT<jats:sub>7<\/jats:sub> receptors) to increase the response to 5\u2010HT. The selective 5\u2010HT<jats:sub>4<\/jats:sub> receptor antagonist GR 113808 (0.1\u2003\u03bc<jats:sc>M<\/jats:sc>) displayed a non\u2010significant trend to inhibit the 5\u2010HT\u2010induced increase.<\/jats:p><\/jats:list-item>\n<jats:list-item><jats:p>Combination experiments with methysergide (1\u2003\u03bc<jats:sc>M<\/jats:sc>), granisetron (1\u2003\u03bc<jats:sc>M<\/jats:sc>) and GR 113808 (0.1\u2003\u03bc<jats:sc>M<\/jats:sc>) revealed that the 5\u2010HT (0.3\u2003\u03bc<jats:sc>M<\/jats:sc>)\u2010induced response consisted of (1) an excitatory component blocked by GR 113808, (2) excitatory and inhibitory components both blocked by methysergide.<\/jats:p><\/jats:list-item>\n<jats:list-item><jats:p>The selective 5\u2010HT<jats:sub>4<\/jats:sub> receptor agonist prucalopride (0.3\u2003\u03bc<jats:sc>M<\/jats:sc>) increased EFS\u2010induced contractions, an effect prevented by GR 113808 (0.1\u2003\u03bc<jats:sc>M<\/jats:sc>).<\/jats:p><\/jats:list-item>\n<jats:list-item><jats:p>The increase of EFS\u2010induced contractions by the preferential 5\u2010HT<jats:sub>2<\/jats:sub> receptor agonist \u03b1\u2010Me\u20105\u2010HT (0.3\u2003\u03bc<jats:sc>M<\/jats:sc>) was antagonized by 5\u2010HT<jats:sub>2B<\/jats:sub> receptor antagonists.<\/jats:p><\/jats:list-item>\n<jats:list-item><jats:p>The 5\u2010HT<jats:sub>1<\/jats:sub>\/5\u2010HT<jats:sub>7<\/jats:sub> receptor agonist 5\u2010carboxamidotryptamine (5\u2010CT; 0.3\u2003\u03bc<jats:sc>M<\/jats:sc>) inhibited EFS\u2010induced contractions. This was prevented by methysergide (1\u2003\u03bc<jats:sc>M<\/jats:sc>), the 5\u2010HT<jats:sub>7<\/jats:sub> receptor antagonist mesulergine (0.3\u2003\u03bc<jats:sc>M<\/jats:sc>) and the selective 5\u2010HT<jats:sub>7<\/jats:sub> receptor antagonist SB\u2010269970 (0.3\u2003\u03bc<jats:sc>M<\/jats:sc>).<\/jats:p><\/jats:list-item>\n<jats:list-item><jats:p>In the presence of GR 113808 (0.1\u2003\u03bc<jats:sc>M<\/jats:sc>), \u03b1\u2010Me\u20105\u2010HT (1\u2003\u03bc<jats:sc>M<\/jats:sc>) increased EFS\u2010induced contractions. The 5\u2010HT (0.3\u2003\u03bc<jats:sc>M<\/jats:sc>)\u2010induced inhibition of the stimulation by \u03b1\u2010Me\u20105\u2010HT was prevented by SB\u2010269970 (0.3\u2003\u03bc<jats:sc>M<\/jats:sc>).<\/jats:p><\/jats:list-item>\n<jats:list-item><jats:p>In conclusion, dog antral longitudinal muscle is endowed with (1) excitatory neuronal 5\u2010HT<jats:sub>4<\/jats:sub> receptors and 5\u2010HT<jats:sub>2B<\/jats:sub> receptors and (2) inhibitory smooth muscle 5\u2010HT<jats:sub>7<\/jats:sub> receptors.<\/jats:p><\/jats:list-item>\n<\/jats:list>\n<\/jats:p><jats:p><jats:italic>British Journal of Pharmacology<\/jats:italic> (2001) <jats:bold>134<\/jats:bold>, 1351\u20131359; doi:<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"doi\" xlink:href=\"10.1038\/sj.bjp.0704376\">10.1038\/sj.bjp.0704376<\/jats:ext-link><\/jats:p>","DOI":"10.1038\/sj.bjp.0704376","type":"journal-article","created":{"date-parts":[[2005,1,28]],"date-time":"2005-01-28T21:35:16Z","timestamp":1106948116000},"page":"1351-1359","update-policy":"http:\/\/dx.doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Characterization of the receptors involved in the 5\u2010HT\u2010induced excitation of canine antral longitudinal muscle"],"prefix":"10.1111","volume":"134","author":[{"given":"N H","family":"Prins","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L M A","family":"Akkermans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R A","family":"Lefebvre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J A J","family":"Schuurkes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2009,1,29]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(19)49479-9"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2982.1990.tb00036.x"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.2042-7158.1995.tb05782.x"},{"key":"e_1_2_6_5_1","first-page":"631","article-title":"Gastrointestinal prokinetic benzamides: the pharmacology underlying stimulation of motility","volume":"47","author":"BRIEJER M.R.","year":"1995","journal-title":"Pharmacol. Rev."},{"key":"e_1_2_6_6_1","first-page":"A705","article-title":"R093877 dose\u2010dependently accelerates delayed gastric emptying in conscious dogs","volume":"112","author":"BRIEJER M.R.","year":"1998","journal-title":"Gastroenterology"},{"key":"e_1_2_6_7_1","first-page":"79","article-title":"Cisapride and 5\u2010hydroxytryptamine enhance motility in the canine antrum via separate pathways, not involving 5\u2010hydroxytryptamine1,2,3,4 receptors","volume":"264","author":"DE RIDDER W.J.","year":"1993","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm00006a001"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1994.tb14064.x"},{"key":"e_1_2_6_10_1","first-page":"P8","article-title":"Extensive pharmacological study of the G protein\u2010coupled fraction of human 5\u2010HT receptors using agonist radioligand binding","volume":"358","author":"GOMMEREN W.","year":"1998","journal-title":"Naunyn-Schmiedebergs' Arch. Pharmacol."},{"key":"e_1_2_6_11_1","first-page":"240","article-title":"SC\u201049518 enhances gastric emptying of solid and liquid meals and stimulates gastrointestinal motility in dogs by a 5\u2010hydroxytryptamine4 receptor mechanism","volume":"264","author":"GULLIKSON G.W.","year":"1993","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0703357"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm991151j"},{"key":"e_1_2_6_14_1","first-page":"282","article-title":"Evidence for functional smooth muscle 5\u2010HT7 receptors mediating inhibition of canine antral longitudinal muscle","volume":"11","author":"PRINS N.H.","year":"1999","journal-title":"Neurogastroenterol. Mot."},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0700954"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0703985"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(89)90695-X"},{"key":"e_1_2_6_18_1","first-page":"199","article-title":"5\u2010HT4 receptors on the human stomach","volume":"3","author":"SCHUURKES J.A.J.","year":"1991","journal-title":"J. Gastrointest. Mot."},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(99)00321-0"}],"container-title":["British Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1038%2Fsj.bjp.0704376","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1038%2Fsj.bjp.0704376","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1038\/sj.bjp.0704376","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T11:32:28Z","timestamp":1697542348000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1038\/sj.bjp.0704376"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,11]]},"references-count":18,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2001,11]]}},"alternative-id":["10.1038\/sj.bjp.0704376"],"URL":"https:\/\/doi.org\/10.1038\/sj.bjp.0704376","archive":["Portico"],"relation":{},"ISSN":["0007-1188","1476-5381"],"issn-type":[{"value":"0007-1188","type":"print"},{"value":"1476-5381","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,11]]},"assertion":[{"value":"2009-01-29","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}